2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombocytopenias, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant
PAPER

4866 Apixaban vs. rivaroxaban after venous thromboembolism in patients with polycythemia vera or essential thrombocythemia: A propensity matched analysis of short-term outcomes

Sangam Sangam, MD, Jayasree Krishnan, MD, MSPH2, Wajeeha Aiman, MD3, Shorabh Sharma, MD4, Kimberly Newman, MD5
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
4 SBH Health System/CUNY School of Medicine, Bronx, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Background:
Patients with myeloproliferative neoplasms (MPNs), such as Polycythemia Vera (PV) or Essential Thrombocythemia (ET), confer an increased risk of venous and arterial thrombosis. However, bleeding events are also frequent due to disease-related complications, including acquired Von Willebrand disease and platelet dysfunction or antiplatelet (APT) and anticoagulant (AC) therapies. Selecting an anticoagulant therefore requires balancing the prevention of recurrent venous thromboembolism (VTE) and arterial thromboembolism (ATE) against bleeding risk. Although apixaban and rivaroxaban are frequently used after VTE, direct comparative evidence in PV/ET is limited. We compared real-world short-term thrombotic, bleeding, and mortality outcomes after initial treatment of VTE with these agents.

Methods:
We performed a retrospective cohort study using the TriNetX Global Collaborative Network. Adults with PV or ET and a first recorded pulmonary embolism (PE) or acute lower-extremity deep vein thrombosis (DVT) were included if apixaban or rivaroxaban was initiated within 30 days of VTE and no oral anticoagulant was recorded during the preceding year. The qualifying VTE was the index event. Separate 1:1 propensity score-matched analyses were performed for each follow-up window for demographic, cardiovascular/cerebrovascular, metabolic/renal, thrombotic, tobacco-use, and hydroxyurea covariates. Recurrent VTE diagnoses were assessed from days 30 to 180. Arterial thromboembolism (ATE), upper and lower gastrointestinal (GI) bleeding, intracranial hemorrhage (ICH), other bleeding, and mortality were assessed at 3 months (90 days) and 6 months (180 days). Kaplan-Meier methods and Cox analyses were performed to generate hazard ratios (HRs) and 95% confidence intervals (CIs); reported P values were obtained from log-rank tests.

Results:
Matching yielded 901 patients per group for ATE, GI bleeding, and mortality analyses. Mean age at index was 58.2 years in the apixaban group and 57.6 years in the rivaroxaban group. By 90 days, ATE occurred in 73 apixaban recipients (8.1%) and 73 rivaroxaban recipients (8.1%; HR, 1.01; 95% CI, 0.73-1.40). By 180 days, ATE occurred in 91 apixaban recipients (10.1%) and 87 rivaroxaban recipients (9.7%; HR, 1.06; 95% CI, 0.79-1.42). Upper-GI bleeding occurred in 50 apixaban recipients (5.5%) and 53 rivaroxaban recipients (5.9%) by 90 days (HR, 0.95; 95% CI, 0.65-1.40), and in 62 (6.9%) and 65 (7.2%) recipients, respectively, by 180 days (HR, 0.96; 95% CI, 0.68-1.36). Lower-GI bleeding occurred in 46 apixaban recipients (5.1%) and 37 rivaroxaban recipients (4.1%) by 90 days (HR, 1.27; 95% CI, 0.82-1.95), and in 61 (6.8%) and 49 (5.4%) recipients, respectively, by 180 days (HR, 1.27; 95% CI, 0.87-1.85). Neither ATE nor the GI-bleeding composite differed significantly between treatment groups. Mortality occurred in 82 apixaban recipients (9.1%) and 73 rivaroxaban recipients (8.1%) by 90 days (HR, 1.14; 95% CI, 0.83-1.56), and in 114 (12.7%) and 97 (10.8%) recipients, respectively, by 180 days (HR, 1.19; 95% CI, 0.91-1.56). Recurrent VTE during days 30-180 occurred in 318 apixaban recipients (41.0%) and 360 rivaroxaban recipients (46.4%; risk difference, -5.4 percentage points; 95% CI, -10.3 to -0.5; HR, 0.848; 95% CI, 0.729-0.986; log-rank P=.031). Intracranial and other bleeding outcomes could not be estimated because of insufficient counts.

Conclusions:
Among propensity-matched patients with PV or ET receiving anticoagulation after VTE, apixaban and rivaroxaban demonstrated similar observed risks of arterial thrombosis, GI bleeding, and mortality. Apixaban was associated with fewer recurrent VTEs through 180 days, showing a potential effectiveness advantage for recurrent VTE prevention. These findings support broadly comparable real-world effectiveness and safety, with apixaban showing an advantage for recurrent VTE prevention. Further prospective studies are needed to validate these findings.

Kimberly Newman, MD: No relevant conflicts of interest to declare.